Literature summary for 3.4.23.16 extracted from

Rhee, S.Y.; Taylor, J.; Fessel, W.J.; Kaufman, D.; Towner, W.; Troia, P.; Ruane, P.; Hellinger, J.; Shirvani, V.; Zolopa, A.; Shafer, R.W.
HIV-1 protease mutations and protease inhibitor cross-resistance (2010), Antimicrob. Agents Chemother., 54, 4253-4261.

Search for more literature for 3.4.23.16

Protein Variants

Protein Variants	Comment	Organism
D30N	the mutation is associated with decreased susceptibility to protease inhibitor nelfinavir	Human immunodeficiency virus 1
F53L	the mutation is associated with decreased susceptibility to protease inhibitor saquinavir	Human immunodeficiency virus 1
G48V	the mutation is associated with decreased susceptibility to protease inhibitor saquinavir and nelfinavir	Human immunodeficiency virus 1
G73S	the mutation is associated with decreased susceptibility to protease inhibitors saquinavir, indinavir and nelfinavir	Human immunodeficiency virus 1
I47AV	the mutation is associated with decreased susceptibility to protease inhibitors atazanavir and lopinavir	Human immunodeficiency virus 1
I47V	the mutation is associated with decreased susceptibility to protease inhibitors darunavir and tipranavir	Human immunodeficiency virus 1
I50V	the mutation is associated with decreased susceptibility to protease inhibitors atazanavir, darunavir and lopinavir	Human immunodeficiency virus 1
I54AMV	the mutation is associated with decreased susceptibility to protease inhibitor tipranavir	Human immunodeficiency virus 1
I54LM	the mutation is associated with decreased susceptibility to protease inhibitor atazanavir and darunavir	Human immunodeficiency virus 1
I54LMV	the mutation is associated with decreased susceptibility to protease inhibitor lopinavir	Human immunodeficiency virus 1
I54TV	the mutation is associated with decreased susceptibility to protease inhibitor saquinavir	Human immunodeficiency virus 1
I54V	the mutation is associated with decreased susceptibility to protease inhibitors indinavir and nelfinavir	Human immunodeficiency virus 1
I84AV	the mutation is associated with decreased susceptibility to protease inhibitor atazanavir, saquinavir, indinavir, lopinavir and nelfinavir	Human immunodeficiency virus 1
I84V	the mutation is associated with decreased susceptibility to protease inhibitors darunavir and tipranavir	Human immunodeficiency virus 1
K43T	the mutation is associated with decreased susceptibility to protease inhibitor tipranavir	Human immunodeficiency virus 1
L10F	the mutation is associated with decreased susceptibility to protease inhibitors atazanavir, lopinavir and indinavir	Human immunodeficiency virus 1
L10FI	the mutation is associated with decreased susceptibility to protease inhibitor nelfinavir	Human immunodeficiency virus 1
L24I	the mutation is associated with decreased susceptibility to protease inhibitors lopinavir and indinavir	Human immunodeficiency virus 1
L33F	the mutation is associated with decreased susceptibility to protease inhibitors atazanavir, darunavir, tipranavir and lopinavir	Human immunodeficiency virus 1
L76V	the mutation is associated with decreased susceptibility to protease inhibitors atazanavir, darunavir, indinavir and lopinavir	Human immunodeficiency virus 1
L89V	the mutation is associated with decreased susceptibility to protease inhibitor darunavir	Human immunodeficiency virus 1
L90M	the mutation is associated with decreased susceptibility to protease inhibitors saquinavir, indinavir and nelfinavir	Human immunodeficiency virus 1
M46IL	the mutation is associated with decreased susceptibility to protease inhibitors atazanavir, nelfinavir, indinavir and lopinavir	Human immunodeficiency virus 1
N83D	the mutation is associated with decreased susceptibility to protease inhibitor tipranavir	Human immunodeficiency virus 1
N88DS	the mutation is associated with decreased susceptibility to protease inhibitor nelfinavir	Human immunodeficiency virus 1
N88S	the mutation is associated with decreased susceptibility to protease inhibitor indinavir	Human immunodeficiency virus 1
T74P	the mutation is associated with decreased susceptibility to protease inhibitors darunavir and tipranavir	Human immunodeficiency virus 1
V32I	the mutation is associated with decreased susceptibility to protease inhibitors atazanavir, darunavir, lopinavir and indinavir	Human immunodeficiency virus 1
V82AFST	the mutation is associated with decreased susceptibility to protease inhibitor lopinavir	Human immunodeficiency virus 1
V82F	the mutation is associated with decreased susceptibility to protease inhibitors atazanavir and nelfinavir	Human immunodeficiency virus 1
V82LT	the mutation is associated with decreased susceptibility to protease inhibitor tipranavir	Human immunodeficiency virus 1

Inhibitors

Inhibitors	Comment	Organism
atazanavir	-	Human immunodeficiency virus 1
darunavir	-	Human immunodeficiency virus 1
fosamprenavir	-	Human immunodeficiency virus 1
indinavir	-	Human immunodeficiency virus 1
lopinavir	-	Human immunodeficiency virus 1
nelfinavir	-	Human immunodeficiency virus 1
saquinavir	-	Human immunodeficiency virus 1
tipranavir	-	Human immunodeficiency virus 1

Organism

Organism	UniProt	Comment	Textmining
Human immunodeficiency virus 1	-	-	-

Synonyms

Synonyms	Comment	Organism
HIV-1 protease	-	Human immunodeficiency virus 1